RecruitingVasodilatory Hypotension During or After Cardiac Surgery
ANG-First Trial (Angiotensin II as First-Line Vasopressor Therapy in Cardiac Surgery)
Eligible age
18+ yrs
Accepts
All genders
Locations
1 state
Healthy volunteers
Yes
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
The purpose of this research is to evaluate the use of Angiotensin II in patients with low blood pressure post-surgery. Your information will be collected for 28 days post the procedure and initiation of the study drug to assess for safety events and complications.
Sponsor: University of Maryland St. Joseph Medical Center
You may qualify if…
- ✓ Adult patients ≥ 18 years of age undergoing cardiac surgery requiring CPB
- ✓ Patients must have clinical features of vasodilation as determined by a MAP \< 65 mmHg that is non-transient in the opinion of the treating physician
- ✓ Patients must be adequately volume resuscitated in the opinion of the treating physician
- ✓ Systemic Vascular Resistance index (SVRi) \< 1970 dynes·sec/cm⁵/m² to support the clinical diagnosis of vasodilation; if no pulmonary artery catheter is in place, vasodilatory hypotension diagnosis according to the judgement of the critical care team
- ✓ Biventricular systolic function is at or greater than pre-cardiopulmonary bypass baseline as demonstrated by echocardiographic evaluation, or the patient is concomitantly treated with
You may not qualify if…
- ✕ Bleeding as primary etiology of hypotension, as determined by \> 4 units RBC transfusion in 24 hours.
- ✕ Patients on ECMO
- ✕ Patients with active endocarditis
- ✕ Patients already on renal replacement therapy or creatinine of \> 4 mg/dl within 2 weeks of surgery
- ✕ Patients with contraindications to Angiotensin II including women who are pregnant or breastfeeding or have active coronary ischemia, mesenteric ischemia, limb ischemia, or high potassium (\> 5.5 meq/L) while receiving Angiotensin II
Where it's recruiting
Maryland
Towson
Source: ClinicalTrials.gov · NCT06487585 · last updated 2025-12-22